April 24, 2024
Metabolism Drugs Market

Metabolism Drugs Market is Expected to be Flourished by Growing Prevalence of Metabolic Disorders

Metabolism drugs are used to regulate metabolic functions in conditions like diabetes, obesity and fatty liver disease. These drugs act on factors like insulin, glucagon and enzymes involved in metabolic pathways. Commonly used metabolism drugs include insulin, metformin, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors to treat type-2 diabetes. Additionally, complementary medicine products like botanicals such as turmeric, berberine and green tea extracts also provide benefits in metabolic regulation.

The global metabolism drugs market is estimated to be valued at US$ 8169.16 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
Growing prevalence of metabolic disorders owing to sedentary lifestyle, obesity and stress has positively impacted the demand for metabolism drugs. The heading refers to this opportunity of flourished market growth driven by metabolic disorder prevalence. According to WHO estimates, over 422 million adults were living with diabetes in 2014 worldwide and the prevalence is expected to increase to over 600 million by 2040. Additionally, obesity rates have almost tripled since the 1970s with over 650 million adults reported as obese in 2016. These metabolic conditions require lifelong therapy involving medications for glycemic control and weight management. Thus, large patient pool and need for better drugs provides strong revenue generation prospects over the forecast period for manufacturers. Furthermore, continuous pipeline of newer drug formulations with improved efficacy for disorders like diabetes and obesity also fuel the market growth. Drugs targeting novel metabolic pathways have demonstrated potential in clinical trials and are expected to enter the market soon.

Segment Analysis
The metabolism drugs market is dominated by the internal medicines segment. This segment accounts for over 55% of the total market share as most metabolic issues such as metabolic syndrome, diabetes, obesity etc require lifelong intake of oral medications. The dietary and nutritional supplements sub-segment is the fastest growing segment growing at a CAGR of around 10% during the forecast period. This is attributed to increasing popularity of nutraceuticals and functional foods among consumers for additional health benefits.

PEST Analysis
Political: The market is regulated by federal regulatory bodies that mandate stringent quality and safety guidelines to be followed by drug manufacturers. Changes in healthcare policies may impact market dynamics.
Economic: As lifestyle diseases surge, economic burden of treatment is rising. The high treatment costs also aid market growth.
Social: Changing lifestyles and dietary patterns have led to rise in metabolic disorders. Growing health awareness drives demand for specialized therapeutic and preventive care options.
Technological: Advances in drug delivery technologies help improve efficacy and compliance. Growing adoption of digital therapeutics and precision medicine aids personalized care delivery.

Key Takeaways
The Global Metabolism Drugs Market Size is expected to witness high growth in the coming years due to the rising prevalence of metabolic disorders worldwide. The global metabolism drugs market is estimated to be valued at US$ 8169.16 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030.

Regionally, North America dominated the market and accounted for over 35% share in 2024 led by the US. The presence of advanced healthcare systems and high healthcare spending fuel market growth in the region.

Key players operating in the metabolism drugs market are Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, ASP Cares, Fagron Compounding Pharmacies, Athenex, Inc., Avella Specialty Pharmacy, Atlas Pharmaceuticals, Empower Pharmacy, Carie Boyd’s Prescription Shop, Edge Pharma, Imprimis NJOF, LLC, IntegraDose Compounding services, LLC, Wells Pharma of Houston, LLC, US Compounding Inc., and SCA Pharma. Increasing strategic collaborations among these players and academia aim to develop innovative treatment options.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it